Internal Medicine
University of Edinburgh spinout Kynos Therapeutics acquired by Dr. Falk Pharma
October 30, 2024Research and Development Edinburgh, Internal Medicine, Microbiology, acquisitions, biopharma, inhibitors
Kynos Therapeutics – a Scottish clinical stage biopharma company focusing on developing novel kynurenine 3-monooxygenase (KMO) inhibitors – has been …
Chiesi announces phase 3 results from enzyme-replacement study
October 29, 2024Research and Development Internal Medicine, Rare Diseases, chiesi Global rare diseases, clinical trials, pharma, rare diseases
Chiesi Global Rare Diseases have announced the results from their BRIGHT trial, which evaluates the efficacy of enzyme-replacement therapy drug …
Eplontersen recommended for EU approval by CHMP for treatment of hereditary transthyretin-mediated amyloidosis
October 21, 2024Research and Development CHMP, EMA, EU, Internal Medicine, gene
Wainzua (eplotersen), produced by AstraZeneca and Ionis, has been recommended for approval in the European Union (EU) by the European …
INDEPENDENT PARSORTIX STUDY HIGHLIGHTS BENEFITS OF COMBINED DNA ANALYSIS IN MELANOMA
August 1, 2024Medical Communications, Research and Development Angle, Internal Medicine, Oncology, Parsortix, melanoma
Multi-analyte approach has potential to guide personalised cancer care CTC mutation profiles associated with more aggressive disease ANGLE plc. a …
Drug discovery and development partnership announced between Apollo Therapeutics and Oxford University
July 31, 2024Clinical Research, Medical Communications, Research and Development Apollo Therapeutics, Internal Medicine, Microbiology, drug development, drug discovery, research
Portfolio therapeutics company Apollo Therapeutics has announced earlier this week that it will provide capital and expertise to Oxford University’s …
Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment
April 25, 2024Medical Communications Ascendis Pharma, Internal Medicine, MHRA, hypoparathyroidism
Ascendis Pharma has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Yorvipath …
Madrigal Pharmaceuticals’ NDA for resmetirom accepted by FDA
September 14, 2023Medical Communications FDA, Internal Medicine, Madrigal Pharma, nash, resmetirom
Madrigal Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application …
